Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

us to begin the clinical trials for our safflower-produced insulin, with the initiation of the animal toxicology study required before the submission of an IND. We intend to submit that IND in the coming months and, if granted approval by the FDA, initiate a Phase I/II trial during the second half of 2008," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Equally as important as insulin, we have initiated preclinical studies to establish functionality of safflower-produced Apo AI(Milano) in animals, the results of which will be critical in confirming our transformative HDL (high density lipoprotein) program. We also continue to execute our growth strategy for our non-pharmaceutical products. In particular, we have launched our second generation oleosome product, Hydresia(TM) G2, and signed Burt's Bees as our first brand name customer. We continue to develop business opportunities to further increase the sales revenues of Botaneco and are currently in discussions with a number of potential customers in this area."

Financials

Please note that prior to the third quarter of 2007, SemBioSys operated under one segment. During the third quarter of 2007, Botaneco completed the construction of its manufacturing facility and SemBioSys began operating in two reportable segments: (i) the Biopharmaceutical, Animal Health, and Nutritional Oils segment focused on the Company's lead pharmaceutical candidates, recombinant human insulin and Apo AI, in addition to its animal health product, ImmunoSphere(TM) and nutritional oils, DHA and GLA and (ii) the Specialty Ingredients segment which will manufacture and market branded lines of naturally derived base emulsions and delivery systems used in the development of cosmetic, personal care and prescription topical/dermatology products through the Botaneco subsidiaries.

Total revenue for the three-month period ended March 31, 2008 was $210,027 compared with $542,788 for the corresponding period in 2007.
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 27, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( ... out of a blog post on Friday, June 24, ... Company,s common stock fell more than 20% and more ... http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The author of the blog post ...
... subsidiary of Eisai Inc., announced today that it has successfully ... its employees, more than 5 times as much as it ... number equates to over 40 pounds of food donated per ... through collaboration with Philabundance, the area,s largest food bank and ...
... CRANBURY, N.J., June 27, 2011 Amicus Therapeutics (Nasdaq: ... forefront of developing therapies for rare diseases, today announced ... Russell 3000® and small-cap Russell 2000® Indexes. The Company ... Friday, June 24, 2011, when Russell Investments reconstituted its ...
Cached Biology Technology:Generex Provides Clarification of Facts 2Generex Provides Clarification of Facts 3Generex Provides Clarification of Facts 4Generex Provides Clarification of Facts 5Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 2Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 3Amicus Therapeutics Joins Russell 3000® Index 2
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... scientists have developed a technique to create 3-D images that ... mathematician. This technique uses anisotropic triangles triangles with ... to create 3-D "mesh" computer graphics of more accurate approximations ... shorter amount of time than current techniques. These types of ...
... MOUNT VERNON, WA--In the mild coastal climate of western ... of growing popular fresh-market vegetables in high tunnel production ... vegetable crops, including protection from environmental stresses such as ... obvious benefits, the use of high tunnels for growing ...
... 19, 2013  Organovo Holdings, Inc. (NYSE MKT: ONVO) (" Organovo ... bioprinting technology, has been invited to present at the 25th ... New York December 3-4, 2013. ... Murphy , will be presenting on Wednesday, December 4, at ...
Cached Biology News:UT Dallas computer scientists create 3-D technique 2High tunnel, open-field production systems compared for lettuce, tomato 2Organovo to Present at the 25th Annual Piper Jaffray Healthcare Conference 2
NNT-1/BSF-3 (N-14)...
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
... cells of embryonal carcinoma of testis and ovary ... like seminoma. Glandular epithelium of yolk sac tumor ... cells of stomach and acini cells of pancreas ... Epitope: Carbohydrate portion on human embryonal carcinoma ...
... Endogenous potent vasoconstrictor peptide. Displays ... modulates vascular tonus. ET-1, ET-2, and ET-3 ... genes. ET-2 and ET-3 are similar to ... amino acids, respectively. All three isopeptides produce ...
Biology Products: